Výsledky vyhledávání

Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062

Publikováno v: Cancer Research. 73:P6-09

Background: USON 01062 (O’Shaughnessy J, et al. Proc SABCS, 2010, abst S4-2) showed no improvement in the primary endpoint of disease-free survival (DFS) (median FU 5 yrs: HR 0.84, 95% CI: 0.67-1.05; p = 0.125) with the addition of capecitabine (X)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad355e927777f2b63a3135e192266454
https://doi.org/10.1158/0008-5472.sabcs13-p6-09-01

Zobrazit plný text záznamu

Abstract P2-05-06: Quantitative measurement of HER2 expression in breast cancers: comparison with 'real world' HER2 testing in a multi-center Collaborative Biomarker Study (CBS) and correlation with clinicopathological features

Autor: M Brigino, A. Paquet, JW Adams, Mojgan Haddad, Linda D. Bosserman, S Zrada, L Krekow, D. A. Yardley, Peter A. Kaufman, Jodi Weidler, WE Lawler, Yolanda Lie, Lee S. Schwartzberg, Wei Huang, M Savin, H Einhorn, S Anderson, A Starr

Publikováno v: Cancer Research. 72:P2-05

Background: Accurate determination of HER2 status is critical in determining appropriate therapy for breast cancer patients. The HERmark® assay is a novel method to quantitatively measure HER2 total protein expression (H2T) in breast cancer. In this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e8f08b545e2db3ef4ac6899ae20289c
https://doi.org/10.1158/0008-5472.sabcs12-p2-05-06

Zobrazit plný text záznamu

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim

Autor: F. Zhan, C Stokoe, Kristi McIntyre, CR Osborne, Devchand Paul, Frankie A. Holmes, Joyce A. O'Shaughnessy, Sharon Wilks, L. Guerra, L Krekow, Lina Asmar, Stephen E. Jones, Svetislava J. Vukelja, Scot Sedlacek, Joanne L. Blum

Publikováno v: Cancer Research. 71:P5-18

Background In our original doxorubicin-cyclophosphamide/docetaxel-cyclophosphamide (AC/TC) adjuvant study (JCO 27: 1177–1183, 2009), we reported an incidence of febrile neutropenia (FN) of 5% (8% in women ≥65 years) with the TC regimen without pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d87237044117f3ae75ef923d70b944a0
https://doi.org/10.1158/0008-5472.sabcs11-p5-18-09

Zobrazit plný text záznamu

P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer

Autor: YX Nagarwala, Kristi McIntyre, Joyce A. O'Shaughnessy, RC Gagnon, JM Mahoney, Jenny C. Chang, Virginia Espina, CR Osborne, Lance A. Liotta, L Krekow, Frankie A. Holmes, Michael A. Danso

Publikováno v: Cancer Research. 71:P5-13

Background 15% of curative HER2−positive patients (pts) treated with standard trastuzumab (T)-based chemotherapy regimens recur. Our prior report (ASCO 2011 #506 using only data from paired samples N=49) identified major pathways of resistance: aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::236d42a50aba16b6f82c4815bde26211
https://doi.org/10.1158/0008-5472.sabcs11-p5-13-03

Zobrazit plný text záznamu

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor

Autor: GL Wright, Kristi McIntyre, Joanne L. Blum, Svetislava J. Vukelja, Yunfei Wang, JC Andersen, Joyce A. O'Shaughnessy, AC Rabe, L Krekow, Lina Asmar, Sharon Wilks

Publikováno v: Cancer Research. 71:PD01-01

Introduction: Fulvestrant is an effective endocrine therapy in patients with ER+ metastatic breast cancer (MBC) that has become resistant to non-steroidal aromatase inhibitors (NSAI). Dasatinib is a potent, broad spectrum ATP-competitive inhibitor of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebc53ecebf22f7b1a10227a39efdf082
https://doi.org/10.1158/0008-5472.sabcs11-pd01-01

Zobrazit plný text záznamu

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Autor: Joanne L. Blum, F. Gilberg, Devchand Paul, R Rivera, R.E. Pluenneke, C Brownstein, R. J. Brooks, JE Schwartz, Kristi McIntyre, L Krekow, Stephen E. Jones, Frankie A. Holmes, DL Lindquist, Joyce A. O'Shaughnessy, C Stokoe, J. Pippen, Svetislava J. Vukelja, Scot Sedlacek

Publikováno v: Cancer Research. 70:S4-2

Background: Combination regimens incorporating anthracyclines and taxanes are among the most effective for EBC and are particularly suitable for pts with high-risk disease. Significant efficacy benefit has been shown in phase III trials integrating c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aa302984287e91fc3f3c21928741356
https://doi.org/10.1158/0008-5472.sabcs10-s4-2

Zobrazit plný text záznamu

Incidence of and Predictive Factors for Recovery of Ovarian Function on Letrozole in ER-Positive Breast Cancer Patients in Their Forties Who Cease Menstruating with Adjuvant Chemotherapy

Autor: L. Krekow, R. Collea, S. Papish, A. Negron, R. Resta, S. Vukelja, J. Donato, L. Guerra, L. Asmar, J. O'Shaughnessy

Publikováno v: Cancer Research. 69:6097-6097

Background: We conducted an open-label pilot study of 2 years of aromatase inhibitor (AI) therapy in women in their 40's with ER-positive breast cancer who had ceased menstruating with adjuvant cyclophosphamide-based chemotherapy, had postmenopausal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0041bff7c497744d2134109a94891065
https://doi.org/10.1158/0008-5472.sabcs-09-6097

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání